Protalex receives positive interim review in European phase 1b study of PRTX-100 to treat immune thrombocytopenia
The dose of PRTX-100 for subjects in the next treatment group (6.0 micrograms/kg) will be twice that of the initial starting dosage (3.0 micrograms/kg). PRTX-100, Protalex’s lead drug
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.